



Mankind

Serving Life

April 13, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Outcome of the Board Meeting

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 30 read with Schedule III of the Listing Regulations and with reference to our earlier intimations dated May 21, 2025 and July 24, 2025 in this regard, we wish to inform you that the Board of Directors of the Company, at its meeting held today, has approved the closure/winding-up of Mankind Pharma Lanka (Private) Limited (“WOS”), a wholly owned subsidiary company incorporated in Sri Lanka, as due to changed regulatory requirements, the anticipated business objectives are no longer viable.

There has been no business operations in the aforesaid WOS, and it is not a material subsidiary of the Company.

The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 for aforesaid is enclosed as **Annexure-I**.

The meeting of Board of Directors of the Company commenced at 03:00 P.M. (IST) and concluded at 03:15 P.M. (IST).

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com

Annexure-I

Disclosure as per Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Information of such event
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Not applicable, as there has been no business operations in said entity.
2	Date on which the agreement for sale has been entered into	Not applicable
3	The expected date of completion of sale/disposal	Not applicable
4	Consideration received from such sale/disposal	Not applicable
5	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Not applicable
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Not applicable
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Listing Regulations	Not applicable

MANKIND PHARMA LIMITED